Risperidone is Effective for Wandering and Disturbed Sleep/Wake Patterns in Alzheimer’s Disease

Behavioral and psychological symptoms of dementia (BPSD), especially aggressiveness, wandering, and sleep disturbance, are a major burden for caregivers. Daily sleep/wake patterns and wandering of institutionalized patients with Alzheimer’s disease (AD) were visually monitored, and 34 patients who manifested wandering were selected and randomly classified into 2 groups: the risperidone group and the nonrisperidone group. After an administration of low-dose risperidone for the risperidone group, the BPSD were reassessed. The binding potentials of dopamine D2 receptor for preadministration and postadministration of risperidone were assessed using positron emission tomography (PET) for 1 case. After the use of risperidone, aggressiveness and wandering were reduced and the nighttime sleeping hours were increased. The PET revealed that the binding potential of dopamine receptor was increased after administration of the drug, associated with improved sleep/wake patterns and behavioral abnormality. Possible serotonergic modulation of dopaminergic function might explain the neurobiological basis of the effect of risperidone.

[1]  S. Kapur,et al.  Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. , 1999, The American journal of psychiatry.

[2]  M. Ikeda,et al.  Reducing the burden of caring for Alzheimer's disease through the amelioration of ‘delusions of theft’ by drug therapy , 2002, International journal of geriatric psychiatry.

[3]  J. O'Brien,et al.  Prevalence and pharmacological management of behavioural and psychological symptoms amongst dementia sufferers living in care environments , 2001, International journal of geriatric psychiatry.

[4]  P. Willner,et al.  The Mesolimbic Dopamine System: From Motivation to Action An International Workshop Malta September 25–29, 1989 , 1989, Psychobiology.

[5]  Shitij Kapur,et al.  Dopamine D2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats , 2000, Psychopharmacology.

[6]  S. Yamaguchi,et al.  Psychiatric wandering behaviour in dementia patients correlated with increased striatal dopamine D2 receptor as shown by [11C]YM‐09151–2 and positron emission tomography , 1997 .

[7]  Norman Sartorius,et al.  Behavioral and Psychological Signs and Symptoms of Dementia: A Consensus Statement on Current Knowledge and Implications for Research and Treatment , 1997 .

[8]  J. Baron,et al.  Relations between hypometabolism in the posterior association neocortex and hippocampal atrophy in Alzheimer's disease: a PET/MRI correlative study , 2001, Journal of neurology, neurosurgery, and psychiatry.

[9]  M. Zaudig.  A Risk-Benefit Assessment of Risperidone for the Treatment of Behavioural and Psychological Symptoms in Dementia , 2000, Drug safety.

[10]  B. Lawlor,et al.  A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia , 1999, Neurology.

[11]  N. Volkow,et al.  Distribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[12]  K. Meguro,et al.  Striatal dopamine metabolism correlated with frontotemporal glucose utilization in Alzheimer's disease: A double-tracer PET study , 1997, Neurology.

[13]  R. Lévy,et al.  Psychiatric Phenomena in Alzheimer's Disease. IV: Disorders of Behaviour , 1990, British Journal of Psychiatry.

[14]  K. Meguro,et al.  Therapeutic Psychosocial Intervention for Elderly Subjects With Very Mild Alzheimer Disease in a Community: The Tajiri Project , 2002, Alzheimer disease and associated disorders.

[15]  D. Bliwise,et al.  Sleep in normal aging and dementia. , 1993, Sleep.

[16]  K. Meguro,et al.  Hemispatial visual-searching impairment correlated with decreased contralateral parietal blood flow in Alzheimer disease. , 2001, Neuropsychiatry, neuropsychology, and behavioral neurology.

[17]  M. Albert,et al.  The `subcortical dementia' of progressive supranuclear palsy , 1974, Journal of neurology, neurosurgery, and psychiatry.

[18]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[19]  K. Meguro,et al.  Disturbance in Daily Sleep/Wake Patterns in Patients With Cognitive Impairment and Decreased Daily Activity , 1990, Journal of the American Geriatrics Society.

[20]  K. Meguro,et al.  Striatal dopaminergic transmission and neocortical glucose utilization in Alzheimer's disease: a triple-tracer positron emission tomography study. , 2000, Archives of gerontology and geriatrics.

[21]  K. Meguro,et al.  Sleep disturbance in elderly patients with cognitive impairment, decreased daily activity and periventricular white matter lesions. , 1995, Sleep.

[22]  M. Folstein.  The noncognitive symptoms of Alzheimer's disease , 1994, Journal of the Neurological Sciences.

[23]  K. Meguro,et al.  Cortical glucose metabolism in psychiatric wandering patients with vascular dementia , 1996, Psychiatry Research: Neuroimaging.

[24]  K. Meguro,et al.  Decreased striatal D2 receptor density associated with severe behavioral abnormality in Alzheimer’s disease , 2003, Annals of nuclear medicine.

[25]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[26]  B. Reisberg,et al.  BEHAVE-AD: A Clinical Rating Scale for the Assessment of Pharmacologically Remediable Behavioral Symptomatology in Alzheimer’s Disease , 1987 .

[27]  L. Tune.  Risperidone for the treatment of behavioral and psychological symptoms of dementia. , 2001, The Journal of clinical psychiatry.

[28]  J. Cummings,et al.  The relationship between donepezil and behavioral disturbances in patients with Alzheimer's disease. , 2000, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[29]  M. Vitiello,et al.  Sleep in Alzheimer's disease and the sundown syndrome , 1992, Neurology.

[30]  S. Stone-Elander,et al.  Stereoselective binding of 11C-raclopride in living human brain — a search for extrastriatal central D2-dopamine receptors by PET , 2004, Psychopharmacology.

[31]  R. Myers,et al.  Loss of social group affinity following prefrontal lesions in free-ranging macaques. , 1973, Brain research.

[32]  K. Meguro,et al.  Decreased cortical glucose metabolism correlates with hippocampal atrophy in Alzheimer's disease as shown by MRI and PET. , 1997, Journal of neurology, neurosurgery, and psychiatry.

[33]  S. Kapur,et al.  Serotonin-dopamine interaction and its relevance to schizophrenia. , 1996, The American journal of psychiatry.

[34]  E. Teng,et al.  The Cognitive Abilities Screening Instrument (CASI): A Practical Test for Cross-Cultural Epidemiological Studies of Dementia , 1994, International Psychogeriatrics.

[35]  H. Brodaty,et al.  Psychosis, depression and behavioural disturbances in Sydney nursing home residents: prevalence and predictors , 2001, International journal of geriatric psychiatry.

[36]  J. Baron,et al.  Neocortical and hippocampal glucose hypometabolism following neurotoxic lesions of the entorhinal and perirhinal cortices in the non-human primate as shown by PET. Implications for Alzheimer's disease. , 1999, Brain : a journal of neurology.